PepGen Inc. (PEPG)
3.18
-0.03
(-0.93%)
USD |
NASDAQ |
Sep 09, 14:49
PepGen Debt to Equity Ratio : 0.1346 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.1346 |
| March 31, 2026 | 0.1236 |
| December 31, 2025 | 0.1153 |
| September 30, 2025 | 0.1069 |
| June 30, 2025 | 0.251 |
| March 31, 2025 | 0.1991 |
| December 31, 2024 | 0.1573 |
| September 30, 2024 | 0.1385 |
| June 30, 2024 | 0.1252 |
| March 31, 2024 | 0.1104 |
| December 31, 2023 | 0.1854 |
| Date | Value |
|---|---|
| September 30, 2023 | 0.1623 |
| June 30, 2023 | 0.145 |
| March 31, 2023 | 0.1324 |
| December 31, 2022 | 0.1366 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| March 31, 2021 | |
| December 31, 2020 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.0127 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 141.40M |
| Total Liabilities (Quarterly) | 21.86M |
| Shareholders Equity (Quarterly) | 119.53M |
| Current Ratio | 13.36 |
| Net Debt Paydown Yield | 0.35% |